Philips (NYSE: PHG) announced today that it received CE mark for its latest SmartCT image reconstruction solution.
The company designed SmartCT to support faster, more informed decision-making in the treatment of stroke and other neurovascular conditions. Amsterdam-based Philips plans to showcase the solution — already available in Japan and Canada — at LINNC Paris 2025.
According to a news release, the company built the solution for its Azurion neurobiplane system. The latest generation of SmartCT simplifies and accelerates 3D imaging. It provides neuro-interventionists with real-time views of brain tissue, blood vessels and interventional devices directly in the angio suite.
By removing the need to transfer patients for separate CT imaging, Smart CT delivers faster, clearer and confident care.
SmartCT enables a streamlined workflow that reduces procedural complexity and supports timely intervention. It enables physicians to personalize therapy and reduce uncertainty during time-critical procedures like mechanical thrombectomy. The latest version of the technology includes soft tissue helical cone-beam CT (CBCT) imaging in as little as eight seconds. Its motion-compensated soft tissue imaging helps with restless stroke patients as well.
Philips designed the solution with a dual phase cerebral feature to enable clear visualization of vessel occlusions and collateral blood flow. Its dual viewer allows physicians to overlay and manipulate two 3D volumes side-by-side at tableside to support real-time image fusion and enhanced procedural planning.
“In stroke care, minutes matter — and confidence is everything,” said Dr. Atul Gupta, chief medical officer, Diagnosis & Treatment at Philips. “With this latest generation of SmartCT for intelligent 3D imaging applications, we’re giving neuro interventionalists the imaging tools they need at the exact moment they need them — improving workflow, reducing delays, and ultimately helping to save lives.”
